The FDA’s approval of Omvoh (mirikizumab-mrkz) for Crohn’s disease—its second IBD authorization since 2023—establishes it as the first biologic in >15 years with Phase 3 two-year efficacy data at launch. In the pivotal VIVID-1 trial, 53% of Omvoh-treated patients achieved clinical remission at one year versus 36% on placebo*, with early endoscopic response tripling placebo…